The most effective approach to treating AD is reducing Aβ production, which is achieved by activating α-secretase and inhibiting β- and γ-secretases, increasing the expression of the proteolytic enzymes neprilysin, insulin-degrading enzymes (IDE), and apolipoprotein E (apoE), which are crucial for Aβ degradation and clearance [20,21], and activating the lysosomal and non-lysosomal pathways that are involved in Aβ degradation and clearance [22,23]. The gene discussed is INS; the disease is Alzheimer disease.